江苏东星智慧医疗科技股份有限公司 董事会审计委员会对会计师事务所2023年度履职情况 履行监督职责的情况报告 （二）聘任会计师事务所履行的程序 公司第三届董事会第十次会议、第三届监事会第七次会议及2022年年度股 东大会审议通过了《关于续聘会计师事务所的议案》，同意聘任立信会计师事 务所为公司2023年度审计机构。 二、审计委员会对会计师事务所监督职责情况 2023年4月19日，第三届董事会审计委员会第二次会议审议通过《关于续聘 会计师事务所的议案》，董事会审计委员会查阅了立信会计师事务所有关资格 证照、相关信息，认为其具备足够的专业胜任能力、投资者保护能力、独立性 ，具备证券相关业务审计资格，能够满足公司2023年度审计工作的质量要求。 为保证审计工作的质量和连续性，公司董事会审计委员会同意续聘立信会计师 事务所（特殊普通合伙）为公司2023年度审计机构，并同意将该议案提交公司 第三届董事会第十次会议审议。 三、总体评价 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治 理准则》《国有企业、上市公司选聘会计师事务所管理办法》和《公司章程》 等相关规定，公司董事会审计委员会本着勤勉尽责的原则， ...

公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在 的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化可能 导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制评 价结果推测未来内部控制的有效性具有一定的风险。 二、内部控制评价结论 江苏东星智慧医疗科技股份有限公司 2023年度内部控制自我评价报告 江苏东星智慧医疗科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求(以下简称"企业内部控制规范体系")，结合江苏东星智慧医疗科技股份有 限公司(以下简称"公司"或"东星医疗")内部控制制度和评价办法，在内部控制日 常监督和专项监督的基础上，我们对公司截止2023年12月31日(内部控制评价报告 基准日)的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全、有效的内部控制体系，如实披 露内部控制评价报告是公司董事会的责任；监事会对董事会建立和实施内部控制 进行监督；经理层负责组织领导企业内部控制的日常运行。 公司 ...

证券代码：301290 证券简称：东星医疗 公告编号：2024-019 江苏东星智慧医疗科技股份有限公司 第三届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第三届董事会第十 九次会议于 2024 年 4 月 18 日 12:30 在公司会议室以现场结合通讯的方式召开。 本次会议通知已于 2024 年 4 月 8 日通过邮件的方式送达全体董事。本次会议应 出席董事 7 人，实际出席董事 7 人。会议由董事长万世平先生召集并主持，公司 监事、高级管理人员列席了本次董事会。本次会议的召集、召开和表决程序符合 《公司法》等有关法律法规及《公司章程》的相关规定。 二、董事会会议审议情况 经各位董事认真审议，形成了如下决议： （一）审议通过《关于公司<2023 年度总经理工作报告>的议案》 经审议，董事会认真听取了总经理魏建刚先生所作的《2023 年度总经理工 作报告》，认为 2023 年度公司经营管理层有效执行了董事会、股东大会的各项 决议，使公司保持了持续稳定的 ...

江苏东星智慧医疗科技股份有限公司 审计报告及财务报表 二○二三年度 江苏东星智慧医疗科技股份有限公司 审计报告及财务报表 （2023 年 01 月 01 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-97 | 审计报告 信会师报字[2024]第 ZA11250 号 江苏东星智慧医疗科技股份有限公司全体股东： 一、 审计意见 我们审计了江苏东星智慧医疗科技股份有限公司（以下简称东星 医疗）财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债 表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、 合并及母公司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥433.73 million, a decrease of 1.89% compared to ¥442.10 million in 2022[20]. - The net profit attributable to shareholders for 2023 was approximately ¥97.22 million, down 5.15% from ¥102.51 million in 2022[20]. - The net profit after deducting non-recurring gains and losses was approximately ¥68.16 million, a significant decrease of 27.89% from ¥94.51 million in 2022[20]. - The total assets at the end of 2023 were approximately ¥2.39 billion, reflecting a slight increase of 0.41% from ¥2.38 billion at the end of 2022[20]. - The net assets attributable to shareholders increased by 2.17% to approximately ¥2.24 billion at the end of 2023, compared to ¥2.19 billion at the end of 2022[20]. - The basic earnings per share for 2023 were ¥0.97, a decrease of 27.07% from ¥1.33 in 2022[20]. - The weighted average return on equity for 2023 was 4.40%, down from 8.40% in 2022[20]. - The company reported a net profit of approximately ¥25.81 million in Q4 2023, with total revenue for the quarter reaching approximately ¥122.62 million[23]. - Total revenue for 2023 was approximately CNY 433.73 million, a decrease of 1.89% compared to CNY 442.10 million in 2022[54]. - Revenue from the medical device sector was CNY 328.46 million, accounting for 75.73% of total revenue, with a year-on-year increase of 4.58%[54]. - Sales of low-value consumables increased by 28.93% to CNY 48.54 million, while sales of surgical staplers decreased by 1.59% to CNY 180.35 million[54]. - The gross profit margin for the medical device sector was 53.25%, down by 3.85% from the previous year[55]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 6 RMB per 10 shares (including tax) to all shareholders based on the total share capital as of the dividend record date for 2023[3]. - The company has not proposed any bonus shares for the 2023 fiscal year, indicating a focus on cash dividends instead[3]. - The cash dividend for 2023 is set at 6 CNY per 10 shares, with a total distribution of 59,362,969.80 CNY, representing 61.06% of the net profit attributable to shareholders[152]. - The total cash dividend amount, including other methods, for the reporting period is 84,346,212.30 CNY, which is 100% of the distributable profit[152]. - The company has a cash dividend policy that requires a minimum of 20% of profits to be distributed during profit allocation[152]. Research and Development - The company reported a research and development (R&D) investment of ¥27,114,546.70 in 2023, representing 6.25% of its operating revenue, an increase from 5.48% in 2022[68]. - The number of R&D personnel increased by 10.64% from 94 in 2022 to 104 in 2023, with R&D personnel now accounting for 16.10% of the total workforce[68]. - The company has completed the development of several new medical devices, including a high-end electric hydraulic operating table and a disposable electric anal ligator, aimed at expanding its product line and enhancing brand value[68]. - The company is developing a self-cleaning puncture device for endoscopes to enhance image clarity during procedures, which is expected to increase revenue from new product lines[64]. - The company is working on a biodegradable tissue clip that will fully absorb within 180 days post-surgery, addressing current material limitations and enhancing market competitiveness[64]. - The introduction of multi-use clamping devices is designed to enhance operational safety and reliability, with a focus on clinical acceptance[64]. - The company has developed a new absorbable suture loading laparoscopic component, addressing the issue of non-absorbable sutures and improving the quality of suture formation[65]. - The new fully electric laparoscopic cutting stapler features advanced electric control systems, enhancing operational efficiency and market competitiveness[65]. - The company is advancing the development of a laparoscopic thyroid surgery retractor, which simplifies and enhances the surgical process while minimizing patient trauma[65]. Market and Competitive Position - The global medical device market size reached $565 billion in 2022, with an expected growth to $605 billion in 2023, and projected to reach $913 billion by 2030, reflecting a CAGR of 6.18% from 2022 to 2030[30]. - The Chinese medical device market size was approximately ¥944 billion in 2022, expected to grow to ¥1,045 billion in 2023, and projected to reach ¥1,652 billion by 2030, with a CAGR of 7.3% from 2022 to 2030[31]. - The company is focusing on technological innovation and product upgrades to enhance competitiveness in the medical device market[31]. - The company is actively participating in the expansion of the laparoscopic stapler market, which is expected to grow significantly due to increasing demand for minimally invasive surgical procedures[32]. - The company has established a comprehensive supplier management system to ensure quality in raw material procurement[41]. - The company has a strong geographic advantage, with a significant portion of domestic stapler manufacturers located in its home city, Changzhou, enhancing its market competitiveness[49]. - The company is positioned as an industry leader with its innovative endoscopic heating device, which has no direct competitors in the domestic market[65]. Governance and Compliance - The financial report is guaranteed to be true, accurate, and complete by the company's board of directors and management[3]. - The company is committed to ensuring compliance with relevant regulations and maintaining transparency in its financial reporting[3]. - The company has outlined its governance structure and responsibilities in the report, ensuring accountability and oversight[6]. - The company emphasizes transparency and timely information disclosure, with the chairman as the primary responsible person for information disclosure[116]. - The company has established a governance structure that includes an audit committee, nomination committee, and strategic investment committee, with independent directors holding over 50% of the positions in key committees[115]. - The company has a dedicated financial department with independent financial decision-making capabilities, ensuring financial independence from controlling shareholders[120]. - The company has established an independent human resources management system, ensuring that its personnel management is separate from that of its controlling shareholders[120]. - The company has a clear ownership structure of its assets, with no instances of asset occupation by controlling shareholders[119]. Strategic Initiatives - The company plans to expand its product offerings with the acquisition of medical equipment companies, including a 100% stake in Sanfeng Dongxing Medical Equipment Co., Ltd.[82]. - The company is exploring potential mergers and acquisitions to bolster its market position and technological capabilities[173]. - The company plans to enhance R&D investment to improve product structure and accelerate product iteration, focusing on innovative products such as electric laparoscopic staplers and ultrasonic knives[105]. - The company aims to leverage its existing product lines to introduce technologically advanced products, enhancing overall market competitiveness and profitability[66]. - The company is committed to expanding its market presence through strategic product development and technological advancements[65]. Risks and Challenges - The company emphasizes the importance of risk awareness regarding forward-looking statements and potential operational risks in its future development outlook[3]. - A risk identified is the potential decline in product prices due to the "volume-based procurement" policy, which could impact revenue and profit margins[102]. - The company is at risk of goodwill impairment if acquired subsidiaries do not perform as expected, potentially affecting profitability[108]. - The company faces risks from price declines in the stapler parts business due to "volume-based procurement" policies, which may impact profitability[104]. Employee and Management - The total number of employees at the end of the reporting period is 646, with 55 in the parent company and 591 in major subsidiaries[146]. - The professional composition includes 376 production personnel, 109 sales personnel, 84 technical personnel, 24 financial personnel, and 53 administrative personnel[146]. - The company has established a comprehensive internal training system to enhance employee skills and business quality[148]. - The company has a stable management team with extensive experience in the medical device industry, contributing to its high reputation and resource accumulation among large hospitals and distributors[50]. Social Responsibility - The company actively engaged in social responsibility, including a donation of equipment worth CNY 250,000 to Changzhou University[167]. - The company emphasizes environmental protection and sustainable development as part of its operational strategy[167]. - The company has committed to a profit distribution policy and dividend return plan for the three years following its IPO, ensuring the protection of investors' rights[177].

江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第三届监事会第 十七次会议于 2024 年 4 月 18 日下午 15:00 在公司会议室以现场方式召开。本次 会议通知已于 2024 年 4 月 8 日通过邮件的方式送达全体监事。本次会议由监事 会主席朱慧玲主持，会议应出席监事 3 人，实际出席监事 3 人。公司董事会秘书 列席会议。本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定。 二、监事会会议审议情况 与会监事经过审议，表决通过了以下议案： （一）审议通过《关于公司<2023 年度监事会工作报告>的议案》 经审议，监事会认为：2023 年公司监事会全体成员根据《公司法》、《证 券法》及其他相关法律、法规、规章以及《公司章程》等有关规定，本着对全体 股东负责的态度，从切实维护公司利益和股东权益出发，认真地履行了监事会职 能，积极地开展相关工作。依法对公司运作情况进行了监督，维护了公司及股东 的合法权益。 证券代码：301290 证券简称：东星医疗 公告编号：2024-020 江苏东星智慧医疗科技股份有限公司 第三届监事会第十七次会议决议公告 本公司及监事会全体成员保证信 ...

证券代码：301290 证券简称：东星医疗 公告编号：2024-024 江苏东星智慧医疗科技股份有限公司 关于公司2023年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司(以下简称"公司")于2024年4月18日 召开第三届董事会第十九次会议和第三届监事会第十七次会议，审议通过了 《关于公司2023年度利润分配预案的议案》，本议案尚需公司2023年年度股 东大会审议。现将相关情况公告如下： 一、2023年度利润分配预案基本情况 二、利润分配方案的合法性、合规性 公司2023年度利润分配预案符合《公司法》《证券法》《企业会计准则》 《关于进一步落实上市公司现金分红有关事项的通知》《上市公司监管指引第3 号—上市公司现金分红》及《公司章程》等规定，符合公司确定的利润分配政 策和分红回报规划，有利于全体股东共享公司经营成果。该利润分配方案具备 合法性、合规性、合理性。 三、履行的审批程序及相关意见 1.董事会审议情况 公司于2024年4月18日召开第三届董事会第十九次会议，审议通过了《关于 公司2023年度利润 ...

华泰联合证券有限责任公司 关于江苏东星智慧医疗科技股份有限公司 2023年度募集资金存放和使用情况专项核查报告 华泰联合证券有限责任公司（以下简称"华泰联合证券"）作为江苏东星智 慧医疗科技股份有限公司（以下简称"东星医疗"、"公司"）首次公开发行股 票的保荐人，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第2 号——上市公司募集资金管理和使用的监管要求》《深圳证券交易所创业板股票 上市规则》及《深圳证券交易所上市公司自律监管指引第13号——保荐业务》等 法律法规的规定，对东星医疗在2023年度募集资金存放与使用情况进行了核查， 核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会《关于同意江苏东星智慧医疗科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]1922 号）同意注册，并经深圳 证券交易所同意，东星医疗首次公开发行人民币普通股（A 股）股票 2,504.3334 万股，每股面值为人民币 1 元，发行价格为每股人民币 44.09 元，募集资金总额 为人民币 1,104,160,596.06 元，扣除发行费用 101,587,9 ...

证券代码：301290 证券简称：东星医疗 公告编号：2024-029 江苏东星医疗科技股份有限公司 关于2024年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）2024年度日常关联交易概述 江苏东星医疗科技股份有限公司(以下简称"东星医疗"或"公司")于2024年4月18 日召开第三届董事会第十九次会议和第三届监事会第十七次会议，审议通过了 《关于2024年度日常关联交易预计的议案》，关联董事万世平、万正元回避表 决，本议案已经公司第三届董事会2024年第一次独立董事专门会议审议通过， 保荐人华泰联合证券有限责任公司出具了专项核查意见。 | 关联 | | 关联交 | | | 实际发生 | 实际发生 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 关联 | | | 实际发生金 | 预计 | 额占同类 | 额与预计 | 披露日期及索 | | 交易 | 人 | 易 | 额 | 金额 | 业务比例( | 金额差异( | 引 | | 类别 | | ...

Financial Performance - The company's revenue for Q1 2024 was ¥91,814,686.88, representing a 9.27% increase compared to ¥84,021,879.90 in the same period last year[5] - Net profit attributable to shareholders for Q1 2024 was ¥19,890,650.72, up 10.56% from ¥17,991,124.69 in the previous year[5] - The total operating revenue for Q1 2024 was CNY 91,814,686.88, an increase of 9.6% compared to CNY 84,021,879.90 in the same period last year[20] - The net profit for Q1 2024 was CNY 19,593,040.69, an increase of 5.54% compared to CNY 18,564,740.94 in Q1 2023[22] - The operating profit for Q1 2024 was CNY 23,846,785.88, up from CNY 21,863,324.32 in the same period last year, reflecting a growth of 9.05%[22] Cash Flow and Assets - The net cash flow from operating activities increased by 86.66% to ¥23,671,274.75, compared to ¥12,681,513.81 in the same period last year[5] - Cash received from tax refunds decreased by 78.00%, totaling 1,023,901.53 compared to 4,653,971.94 in the prior period[9] - Cash payments for various taxes decreased by 48.97%, amounting to 12,733,922.03 compared to 24,953,627.21 previously[9] - The cash and cash equivalents at the end of Q1 2024 were CNY 237,281,126.32, down from CNY 698,422,931.47 at the end of Q1 2023[24] - The company's cash and cash equivalents decreased by 57.87% to ¥239,682,701.32 from ¥568,855,578.18 at the beginning of the year[8] Investment and Expenses - The company reported a significant increase in investment income, rising 6748.64% to ¥12,082,100.02 from ¥176,416.07 in the previous year[8] - The company experienced a 34285.78% increase in non-operating expenses, reaching 104,464.00 due to charitable donations[9] - Research and development expenses decreased to CNY 4,804,803.02 from CNY 6,275,458.33, a reduction of 23.49%[22] - Investment activities resulted in a net cash outflow of CNY 326,688,357.82, an improvement from a net outflow of CNY 405,993,575.12 in Q1 2023[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,336[11] - The company repurchased a total of 1,235,051 shares, representing 1.23% of the total share capital, with a total transaction amount of CNY 24,983,242.50[15] Asset Management - The total assets at the end of Q1 2024 were ¥2,358,116,976.03, a decrease of 1.48% from ¥2,393,581,909.51 at the end of the previous year[5] - The total liabilities decreased to CNY 117,304,628.05 from CNY 147,371,481.33, a reduction of 20.4%[19] - The company’s equity attributable to shareholders was CNY 2,233,616,215.44, slightly down from CNY 2,238,716,685.61[19] Future Outlook - The company has ongoing investments in new technologies and products, although specific details were not provided in the report[18] - The company plans to continue its market expansion and may consider further acquisitions in the future[18]